CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus completes large scale enrolment for two Phase III trials of Desidustat05-02-2021
05-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces completion of Phase-I trials of ZY19489-A single dose cure for Malaria in collaboration with MMV04-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst/Institutional Investors' meet01-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
the newspaper cutting dated January 28, 2021 with regard to Notice of Board Meeting of the Company scheduled to be held on Friday, February 5, 2021 published in the Financial Express29-01-2021
USFDA grants orphan drug designation to Zydus Cadila's Saroglitazar Mg
Zydus Cadila on Thursday said the US health regulator has granted orphan drug designation (ODD) to its Saroglitazar Mg used for the treatment of pati28-01-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC)28-01-2021
CADILA HEALTHCARE LTD. - 532321 - Board Meeting Intimation for Unaudited Financial Results
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2021 ,inter alia, to consider and approve Unaudited financial results for the quarter / nine months ended on December 31, 2020.27-01-2021
Zydus Cadila says 'positive results' from phase 2 studies of Covid-19 drug
Drug firm Zydus Cadila on Monday said it has received positive results from phase 2(b) studies of Desidustat in Covid-19 patients conducted in Mexico.25-01-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus' Desidustat shows efficacy and safety in treating Hypoxia in hospitalized Covid-19 patients in Mexico25-01-2021
Zydus Cadila gets US health regulator's nod for thyroid drug
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Liothyronine Sodium tablets USP, 5 mcg, 25 mcg, and 50 mcg, Cadila Healthcare said in a regulatory filing23-01-2021